Primary Outcome Measures Dose-limiting toxicity （DLT） [ Time Frame: After 28 days of single infusion ] Safety Secondary Outcome Measures Maximum tolerated dose (MTD) [ Time Frame: After 28 days of single infusion ] Tolerability Objective response rate (ORR) [ Time Frame: Month 12 ] Clinical response will be assessed by RECIST 1.1. Progression-free survival (PFS) [ Time Frame: Month 12 ] PFS of patients receiving[…]
From the blog
Genetically Modified T-Cells for the Treatment of Mesothelioma and Other Tumors
Genetically modified T cells are a promising treatment for those suffering from mesothelioma. There is only data from five patients, but the results so far look good. The Phase I part of the study is looking at the safety and efficacy of the treatment and is finding out what dosage[…]
Intravenous Magnesium in Patients Receiving Cisplatin
Primary Outcome Measures Feasibility and acceptability as measured by participant rates of enrollment [ Time Frame: 6 months ] Feasibility assessed by % of patients that agree to participate. Project feasible if >30% of the patients approached agree to participate Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0 [ Time Frame: Time[…]
More Peritoneal Mesothelioma Patients Should be Receiving Surgery
Peritoneal mesothelioma is a rare condition with only 400 cases diagnosed every year. Patients diagnosed with the cancer are not living as long as they could because of the underutilization of surgery. Surgery is only performed on a third of patients even though there are people that would benefit and[…]
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Primary Outcome Measures Primary endpoint for cohort 1: Objective response rate (ORR) according to RECIST 1.1 [ Time Frame: At the date of tumor assessment according to RECIST 1.1, assessed up to 2 years after registration ] ORR according to RECIST 1.1 is defined as the proportion of patients, whose best overall response is[…]
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)
Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, ii) non-equivocal[…]
A New Study is Looking at the Combination of Keytruda and ONCOS-102
A new combination of two existing drugs is being tested to treat mesothelioma. Merck and Targovax, which have the drugs Keytruda (pembrolizumab), an immunotherapy drug, and ONCOS-102, a modified adenovirus, are working together in the study. They can both be used on their own alongside chemotherapy to treat mesothelioma, but[…]
High Resolution Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Primary Outcome Measures Prospectively gather information related to the use of high-resolution computed tomographic imaging (HRCT) including photon counting CT (PCCT) scans, together with minimally invasive surveillance for early detection of mesotheliomas in pts with … [ Time Frame: annual or bi-annual followup, 5 years interim analysis ] Documentation of[…]
Chemoperfusion Could help Extend Mesothelioma Sufferers’ Lives
Mesothelioma is a deadly cancer of the mesothelium, which lines the lungs, heart, abdomen, and tunica vaginalis testis after exposure to asbestos. The most common type is pleural mesothelioma, which affects the lining of the lungs. There is no cure, so the best option for people with this cancer is[…]
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO)
Primary Outcome Measures Non-progression proportion [ Time Frame: 6 month after starting talazoparib ] The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST[…]
Skip to content